Shares of Exelixis (EXEL) slipped on Monday after Bank of America downgraded the cancer drugmaker to Underperform from Neutral and lowered its target price to $41 from $43, citing concerns over its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback